Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats major depressive disorder (MDD). Sold as Emsam. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 2 applications for Selegiline (sold as Emsam), first approved Feb 27, 2006, with 1 new use approved and 0 published complete response letters.
First approved: Feb 27, 2006
Applications: 2
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $19.0M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Emsam
Part D
$13.7M
+9%
887
Selegiline HCl
Part D
$4.8M
-5%
10,361
Zelapar
Part D
$534K
-49%
14
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
SELEGILINE HCL 5 MG CAPSULE: $0.754 per unitGeneric · +25% in a year
SELEGILINE HCL 5 MG TABLET: $0.807 per unitGeneric · +5% in a year
EMSAM 12 MG/24 HOURS PATCH: $75.35 per unitBrand · +5% in a year
EMSAM 6 MG/24 HOURS PATCH: $75.04 per unitBrand · +5% in a year
EMSAM 9 MG/24 HOURS PATCH: $75.18 per unitBrand · +5% in a year
FP-ODA drug with a revised indication and a new dosage for the treatment of Parkinson's disease (When used in combination with levodopa-containing products;… · FP Pharmaceutical Corporation · Dec 21, 2015
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA